MedTrace Logo

PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition

NCT07618000 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-06-01

No results posted yet for this study

Summary

The expected outcome of this study is that continuous 8-week supplementation with the PI-YSP-0111 prebiotic formulation will exert beneficial effects on gut microbiota modulation and liver health.

Conditions

  • Heathly Volunteers

Interventions

DIETARY_SUPPLEMENT

PI-YSP-0111 formulation (High-dose)

6 per day(Lactobacillus rhamnosus MB17, Lactobacillus plantarum MB-10, Grape Seed extract, Oligo, Wofberry Extract Powder, Maltose powder, Aerosil, Magnesium Stearate)

DIETARY_SUPPLEMENT

PI-YSP-0111 formulation (Low-dose)

4 per day(Lactobacillus rhamnosus MB17, Lactobacillus plantarum MB-10, Grape Seed extract, Oligo, Wofberry Extract Powder, Maltose powder, Aerosil, Magnesium Stearate)

DIETARY_SUPPLEMENT

Placebo group(High-dose)

6 per day(Maltose powder, Aerosil, Magnesium Stearate)

DIETARY_SUPPLEMENT

Placebo group(Low-dose)

4 per day(Maltose powder, Aerosil, Magnesium Stearate)

Sponsors & Collaborators

  • Yung Shin Pharm. Ind. Co., Ltd.

    collaborator INDUSTRY

  • Taipei Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-08
Primary Completion
2027-04-07
Completion
2027-04-07

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07618000 on ClinicalTrials.gov